LensGen

StarFish Contribution

LensGen is developing an accommodative intraocular lens (AIOL) for the treatment of presbyopia. In 2012, LensGen engaged StarFish Medical to design the world’s first testing device to concurrently quantify the optical properties, accommodative range, force and strain imparted to an AIOL. This device provided a benchtop testing platform to accelerate and influence development activities, prove out theories and design concepts.

$100M Valuation

LensGen has raised a total of $52M to date. Their latest funding of $10M was raised on Aug 20, 2020. It is part of a larger Series B round planned for early 2021 that is earmarked for funding the company through the approval of a pivotal FDA study for its Juvene fluid-optic intraocular lens (IOL) for cataract and presbyopia treatment.

LensGen fluid-optic accommodating intraocular lens shown in protective housing

Ramgopal Rao
Founder and Chief Executive Officer
LensGen Inc.

Test fixture used to quantify stress, strain, and optical quality for accommodating intraocular lenses

Test Fixture to Quantify Stress, Strain, and Optical Quality for AIOLs.

Artificial lens capsule used for intraocular lens testing at StarFish Medical

Artificial Capsule for Lens Testing.